Glenn Davis, MD
Internal Medicine · Chester, NJNPI 1740275858
Payments from drug & device makers
Across 266 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$856
- AbbVie$645
- Novo Nordisk$407
- Lilly USA, LLC$406
- Amgen$224
- Pfizer$220
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,266100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 42 | $856 |
| AbbVie(2 entities) | 35 | $645 |
| Novo Nordisk | 30 | $407 |
| Lilly USA, LLC | 28 | $406 |
| Amgen | 18 | $224 |
| Pfizer | 16 | $220 |
| Boehringer Ingelheim | 15 | $213 |
| Exact Sciences | 7 | $159 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $146 |
| Astellas Pharma US Inc | 6 | $118 |
| GSK | 7 | $118 |
| Merck | 7 | $91 |
| Bayer | 5 | $89 |
| Johnson & Johnson | 6 | $89 |
| Esperion Therapeutics, Inc. | 6 | $85 |
| Kowa Pharmaceuticals America, Inc. | 5 | $63 |
| Abbott | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Genentech USA, Inc. | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $30 |
| Sanofi Pasteur Inc. | 2 | $28 |
| Pulmonx Corporation | 1 | $26 |
| Seqirus USA Inc | 2 | $26 |
| Bausch Health US, LLC | 2 | $26 |
| Renalytix AI, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $11 |
| Althera Pharmaceuticals LLC | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,266 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 76 | $98,640 |
| Dupixent SyringeDupilumab | 13 | $95,174 |
| JardianceEmpagliflozin | 63 | $85,749 |
| EliquisApixaban | 61 | $64,676 |
| OzempicSemaglutide | 55 | $56,526 |
| TrulicityDulaglutide | 43 | $49,421 |
| JanuviaSitagliptin Phosphate | 33 | $38,192 |
| XareltoRivaroxaban | 25 | $28,152 |
| Rosuvastatin Calcium | 440 | $8,927 |
| Atorvastatin Calcium | 659 | $7,691 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,371 |
| SynthroidLevothyroxine Sodium | 79 | $6,498 |
| OxycontinOxycodone Hcl | 11 | $6,287 |
| DexilantDexlansoprazole | 15 | $6,235 |
| SteglatroErtugliflozin Pidolate | 12 | $4,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $856 | $98,64076 claims |
| Boehringer IngelheimJardiance | $213 | $85,74963 claims |
| PfizerEliquis | $220 | $64,67661 claims |
| Novo NordiskOzempic | $407 | $56,52655 claims |
| Lilly USA, LLCTrulicity | $406 | $49,42143 claims |
| MerckJanuvia, Steglatro | $91 | $43,07845 claims |
| Johnson & JohnsonXarelto | $89 | $28,15225 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $118 | $11,15134 claims |
| AbbVieSynthroid | $645 | $6,49879 claims |
| Almatica Pharma LLCSertraline Hcl | $11 | $1,709163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Chester
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.